MIT busts genome reader Navigenics on patents
Navigenics, a Foster City, Calif. company that checks consumers’ genomes for indications of disease, is being sued by the Massachusetts Institute of Technology for allegedly infringing on a patent that the university licensed exclusively to E8 Pharmaceuticals.
If MIT wins the suit, Navigenics will have to pay damages to both the school and E8. It will also have to pay to officially acquire the patent or pay royalties. This patent has been a sticking point before, prompting MIT to sue public company Affymetrix, maker of chips for genome operations, last year. Three months ago, Navigenics acquired Affymetrix Clinical Services Laboratory, including the patent. No resolution was reached in the Affymetrix suit, which will be handled separately from the new case against Navigenics.
Navigenics counts Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures and Sequoia Capital among its investors. Navigenics is a direct competitor of 23andMe, another service that reads genomes for consumers.
Next Story: iPoop developers dare Apple to flush their app
Previous Story: Zeebo ships game consoles to stores in Brazil
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.